Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

The first siRNA drug, patisiran, was approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat a debilitating genetic disorder called hereditary transthyretin amyloidosis.

Generation Bio (GBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from ...

Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, ...

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...

In SNALPs, the backbone-modified siRNA is encapsulated within a closed shell of a cationic-zwitterionic lipid bilayer, furnished with an outer PEG shield (Figure 2A). The lipid bilayer contains a ...

Oofaniin aadaa sirna boo’ichaa giddugala Oromiyaa hawaasa Oromoo naannawa Maccaa, Sadeen Liibanii fi naannawaa sanatti beekamudha. Oofaniin nama hundaaf hin jedhamu; gaafa namni guddaan hawaasa ...